Articles

Kelly Godby, MD, discusses novel triplet combinations and how they are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years. 

Triplet Regimens Dominate the Relapsed/Refractory Myeloma Treatment Landscape

Susan Bal, MD, discusses key trials in the multiple myeloma space.

Quadruplets Poised to Become New Standard in Frontline Transplant-Eligible Myeloma

Videos

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.  



Dr. Costa on the Promising Role of CAR T-Cell Therapy in Multiple Myeloma 

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.  



Dr. Costa on Remaining Challenges With CAR T-Cell Therapy in Multiple Myeloma 

Luciano J. Costa, MD, discusses the emerging role of CAR T-cell therapy in relapsed/refractory multiple myeloma, investigational products such as ide-cel, orva-cel, and JNJ-4528, and early intervention strategies to manage the toxicities associated with these products.

Questions Remain as CAR T-Cell Therapy Prepares to Transform Relapsed/Refractory Myeloma Treatment

Luciano J. Costa, MD, PhD, discusses unmet need​s in relapsed/refractory multiple myeloma. 

University of Alabama at Birmingham

Latest from University of Alabama at Birmingham

New content coming soon, please check back later.